

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Megestrol acetate

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
<p>megestrol acetate suspension (Megace Suspension and Megace ES Suspension)</p> <p>megestrol acetate tablets (Megace tablets)</p>

APPROVAL CRITERIA

Requests for megestrol acetate suspension (Megace Suspension and Megace ES Suspension) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Cachexia, or an unexplained significant weight loss in individuals with HIV/AIDS; **OR**
 - B. Ovarian cancer, including epithelial , fallopian tube, and primary peritoneal cancers (NCCN 2A); **OR**
 - C. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS).

Requests for megestrol acetate tablets (Megace tablets) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Advanced, inoperable, recurrent Breast cancer; **AND**
 - B. Individual is using for palliative management;

OR

 - C. Endometrial/uterine cancer; **AND**
 - D. Individual is using for palliative management;

OR

 - E. Persistent or recurrent Ovarian cancer, including epithelial , fallopian tube, and primary peritoneal cancers (NCCN 2A);

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

OR

F. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS).

Notes:

- I. The use of megestrol acetate tablets in other types of neoplastic disease is not recommended, however, AHFS, DrugPoints, and Clinical Pharmacology all have listed cachexia/anorexia as an off-label indication for megestrol acetate without stating a specific dosage form.
- II. Oral suspensions containing 200 mg/5 mL are *not* bioequivalent or interchangeable on a mg-per-mg basis with the oral suspension containing 625 mg/5 mL (Megace ES).

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 20, 2020.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2020 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 20, 2020.
 - a. Breast Cancer. V5.2020. Revised July 15, 2020.
 - b. Ovarian Cancer. V1.2020. Revised March 11, 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.